Novo Nordisk A/S (NVO)
126.05
-2.59
(-2.01%)
USD |
NYSE |
Apr 24, 13:45
Novo Nordisk Price to Book Value: 35.54 for April 24, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| April 23, 2024 | 36.27 |
| April 22, 2024 | 35.32 |
| April 19, 2024 | 34.60 |
| April 18, 2024 | 34.61 |
| April 17, 2024 | 35.12 |
| April 16, 2024 | 34.81 |
| April 15, 2024 | 34.94 |
| April 12, 2024 | 35.11 |
| April 11, 2024 | 35.36 |
| April 10, 2024 | 35.23 |
| April 09, 2024 | 35.21 |
| April 08, 2024 | 35.94 |
| April 05, 2024 | 35.49 |
| April 04, 2024 | 34.96 |
| April 03, 2024 | 35.81 |
| April 02, 2024 | 35.66 |
| April 01, 2024 | 35.97 |
| March 28, 2024 | 36.21 |
| March 27, 2024 | 36.11 |
| March 26, 2024 | 36.50 |
| March 25, 2024 | 36.40 |
| March 22, 2024 | 36.31 |
| March 21, 2024 | 36.62 |
| March 20, 2024 | 36.77 |
| March 19, 2024 | 37.05 |
| Date | Value |
|---|---|
| March 18, 2024 | 37.48 |
| March 15, 2024 | 37.33 |
| March 14, 2024 | 37.96 |
| March 13, 2024 | 37.65 |
| March 12, 2024 | 38.11 |
| March 11, 2024 | 37.02 |
| March 08, 2024 | 37.53 |
| March 07, 2024 | 38.34 |
| March 06, 2024 | 35.19 |
| March 05, 2024 | 35.16 |
| March 04, 2024 | 36.09 |
| March 01, 2024 | 35.04 |
| February 29, 2024 | 33.79 |
| February 28, 2024 | 34.29 |
| February 27, 2024 | 34.48 |
| February 26, 2024 | 34.84 |
| February 23, 2024 | 34.82 |
| February 22, 2024 | 35.13 |
| February 21, 2024 | 34.11 |
| February 20, 2024 | 34.26 |
| February 16, 2024 | 34.98 |
| February 15, 2024 | 34.35 |
| February 14, 2024 | 34.78 |
| February 13, 2024 | 33.85 |
| February 12, 2024 | 34.00 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
13.44
Minimum
Mar 20 2020
38.34
Maximum
Mar 07 2024
22.64
Average
21.73
Median
Price to Book Value Benchmarks
| Amgen Inc | 23.56 |
| AstraZeneca PLC | 5.642 |
| Sanofi SA | 1.427 |
| Viking Therapeutics Inc | 19.01 |
| Evaxion Biotech AS | -- |
Price to Book Value Related Metrics
| PE Ratio | 46.64 |
| PS Ratio | 16.80 |
| PEG Ratio | 0.8317 |
| Price to Free Cash Flow | 55.74 |
| Price | 126.05 |
| Earnings Yield | 2.14% |
| Market Cap | 562.35B |
| PEGY Ratio | 0.8162 |
| Operating PE Ratio | 38.05 |
| Normalized PE Ratio | 46.64 |